Loxo Oncology, a division of Eli Lilly, and Kumquat Biosciences teamed up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specific immune responses in cancer patients.

Europe’s drug regulator started a real-time review of the Covid-19 vaccine developed by French drugmaker Sanofi and Britain’s GlaxoSmithKline, the fifth shot currently under such a review as of July 20.

Health agencies and vaccine and immunology experts have pushed back against Pfizer and BioNTech’s assertions that a Covid-19 booster shot is necessary.

Maryland-based Altimmune is discontinuing research into the clinical-stage biopharmaceutical firm’s intranasal Covid-19 vaccine following “disappointing” results. 

A mixed schedule of vaccines where a shot of Pfizer’s Covid-19 vaccine is given four weeks after an AstraZeneca shot will produce better immune responses than giving another dose of AstraZeneca, an Oxford study said on June 28.

A third shot of the Oxford-AstraZeneca Covid-19 vaccine produces a strong immune response, researchers said on June 28, adding there was not yet evidence that such shots were needed, especially given shortages in some countries.

Novavax Inc.’s experimental Covid-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.

After months of bad news regarding Covid-19 vaccine manufacturing issues, Emergent BioSolutions posted positive two-year data related to the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.

Pfizer’s Covid-19 vaccine generates antibody responses three-and-a-half times larger in older people when a second dose is delayed to 12 weeks after the first, a British study said.

A second-generation Covid-19 vaccine developed by CureVac and GlaxoSmithKline – designed to protect against coronavirus variants – produced a high level of immune response in a trial in rats, the companies said on May 13.